I
Incyte
Pharmaceutical Research | Oncology Product Development | Incyte.com
About Incyte
In 1991, Incyte Pharmaceuticals was incorporated, born from the assets of a liquidated biotechnology company. Founded by a team that included Roy A. Whitfield as CEO and scientist Randall W. Scott, the company initially focused on genomics, building a massive database of genetic information for the pharmaceutical industry. A pivotal moment came on November 4, 1993, when Incyte went public, raising $15 million and securing the capital needed to expand its gene sequencing programs. A significant transformation occurred in 2002. Sensing an opportunity after a major acquisition in the pharma space, Incyte relocated to Delaware and pivoted from genomics to drug discovery and development. This new focus culminated in the 2011 FDA approval of its first drug, Jakafi (ruxolitinib), a treatment for a rare blood cancer. This success established Incyte as a serious biopharmaceutical player and remains a cornerstone of its portfolio. The company has since expanded its pipeline through strategic partnerships and acquisitions, including the notable $750 million acquisition of Escient Pharmaceuticals in 2024 to bolster its inflammation and autoimmunity portfolio.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1991
- Headquarters
- Wilmington, United States
- Listing
- IPO 1993
- Employees
- 3,541
- Open positions
- 146
- Dealroom signal
- 51.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Research, Developer Tools, Biotechnology, Oncology, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 4 companies, latest Jul 2026
- Capital deployed
- $120M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2023 | $44M | — | Scuti Capital Management | — |
| IPO✓Exit | Nov 1993 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Incyte is 63K monthly website visits, down 13.7% over the last three months. Incyte's team grew 60.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vega TherapeuticsSouth San Francisco, United StatesDeveloping antibody therapies for rare blood disorders. Established by Star Therapeutics
$1.3Bvaluation
Genesis TherapeuticsSan Mateo, United StatesUnifying AI and Biotech We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines
$480Mvaluation
Escient PharmaceuticalsSan Diego, United StatesA privately held biotechnology company
$750Mvaluation
Villaris TherapeuticsCary, United StatesA preclinical-stage biopharmaceutical company
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- SMScuti Capital Management
Other known investors3 additional known investors
Dorothy Koo Boulland
International Biotechnology Trust- PCPaul Chirico
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Incyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Incyte’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.